Answers are grounded in this paper and cite their sources.
Hepatitis C virus (HCV) infection is a major health problem in patients with end-stage renal disease (ESRD). The incidence of acute HCV infection during maintenance dialysis is much higher than that in the general population due to nosocomial transmission. Following acute HCV infection, most patients remain viremic and evolve into chronic infection, leading to chronic hepatitis, cirrhosis, and even hepatocellular carcinoma (HCC). Overall, ESRD patients with chronic hepatitis C (CHC) have an increased risk of liver-related morbidity and mortality, either on maintenance dialysis or after renal transplantation (RT). Interferon (IFN) therapy is modestly effective for HCV infection in ESRD patients. Conventional or pegylated IFN monotherapy has been employed to treat acute hepatitis C (AHC) in ESRD patients with excellent safety and efficacy. Regarding CHC, approximately one third of the patients can achieve sustained virological response (SVR) by conventional or pegylated IFN monotherapy. The introduction of low-dose ribavirin in combination with conventional or pegylated IFN has further improved the SVR rate in treatment-naive or treatment-experienced patients. Similar to HCV-infected patients with normal renal function, baseline viral load, viral genotypes, and ontreatment viral decline are useful for guiding therapy in ESRD patients. Of particular note, IFN-based therapy is not recommended for viremic patients who receive RT because of the low SVR rate and the high risk of acute graft rejection. In conclusion, ESRD patients with HCV infection should be encouraged to receive antiviral therapy. Treated patients who achieve SVR usually have long-term durable virological, biochemical, and histological responses.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: